The efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative study

Basit Öğe Kaydı
dc.contributor.authorDolapcioglu, K.
dc.contributor.authorBoz, A.
dc.contributor.authorBaloglu, A.
dc.date.accessioned2024-09-18T20:16:52Z
dc.date.available2024-09-18T20:16:52Z
dc.date.issued2013
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjectives: This study compared the efficacy of the levonorgestrel-releasing intrauterine device (LNG-IUD) to oral medroxyprogesterone acetate (MPA) applied for the same length of time for the management of endometrial hyperplasia without atypia. Study Design: This was single-center, open, randomized, and clinical trial. One hundred four patients aged between 30-50 years and diagnosed with endometrial hyperplasia without atypia by endometrial biopsy, were randomized to receive LNG-IUD or MPA. Both groups were further divided into two groups as three-month and six-month treatment subgroups. The primary objective was to compare the complete regression rates of hyperplasia, and the secondary objective was to determine the minimum duration of time required for the achievement of regression. Results: At two-year follow-up, the success rates of LNG-IUD treatment and oral MPA for three months therapy were 84% and 50%, respectively. While the regression rate was 100% in the six-month LNG-IUD group, it was 64% in the oral MPA group. LNG-IUD appeared to have a significantly higher success rate (p = 0.0001). Conclusion: It is believed that by this study LNG-IUD applications may be a reliable preference for younger patients who wish to preserve their uterus and especially for non-atypical cases, and if the patient demands fertility, even a six-month application will provide effective treatment.en_US
dc.identifier.endpage126en_US
dc.identifier.issn0390-6663
dc.identifier.issn2709-0094
dc.identifier.issue1en_US
dc.identifier.pmid23724525en_US
dc.identifier.scopus2-s2.0-84876253638en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage122en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12483/9785
dc.identifier.volume40en_US
dc.identifier.wosWOS:000315752800033en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImr Pressen_US
dc.relation.ispartofClinical and Experimental Obstetrics & Gynecologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectEndometrial hyperplasiaen_US
dc.subjectNon-atypicalen_US
dc.subjectTheraphyen_US
dc.subjectLevonorgestrel-releasing intrauterine systemen_US
dc.subjectOral progestinen_US
dc.titleThe efficacy of intrauterine versus oral progestin for the treatment of endometrial hyperplasia. A prospective randomized comparative studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu